poisar

Stocks · News reference

Wedbush Downgrades Aclaris Therapeutics to Neutral

Fiscal.ai

Wedbush has downgraded Aclaris Therapeutics from Outperform to Neutral and reduced its price target for the company's stock.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading